Grifols, S.A. (BME:GRF)

Inozyme Pharma Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Market Capitalization	7,932	5,681	9,231	6,557	9,783	14,161
Market Cap Growth	32.38%	-38.46%	40.77%	-32.97%	-30.92%	-24.52%
Enterprise Value	18,725	17,373	22,245	18,604	18,767	21,924
Last Close Price	12.93	9.15	15.46	10.77	16.88	23.56
PE Ratio	28.61	36.20	218.13	35.44	51.84	22.89
Forward PE	14.28	10.93	16.95	12.71	15.88	20.58
PS Ratio	1.07	0.79	1.40	1.08	1.98	2.65
PB Ratio	1.04	0.66	1.23	0.82	1.34	2.11
P/FCF Ratio	9.54	8.48	-	-	27.98	17.06
P/OCF Ratio	7.18	6.30	42.21	-	16.39	12.75
PEG Ratio	0.43	0.24	0.44	0.35	1.17	1.61
EV/Sales Ratio	2.51	2.41	3.38	3.07	3.80	4.11
EV/EBITDA Ratio	10.40	10.80	17.63	17.19	20.35	16.91
EV/EBIT Ratio	12.73	13.17	23.15	27.71	33.36	22.48
EV/FCF Ratio	22.52	25.94	-	-	53.68	26.41
Debt / Equity Ratio	1.18	1.18	1.47	-	1.39	1.03
Debt / EBITDA Ratio	4.92	5.98	8.21	-	11.02	5.34
Debt / FCF Ratio	10.76	15.11	-	-	29.08	8.34
Asset Turnover	0.35	0.34	0.31	0.30	0.29	0.35
Inventory Turnover	1.28	1.24	1.20	1.40	1.39	1.42
Quick Ratio	0.81	0.87	0.63	0.67	0.92	0.82
Current Ratio	2.64	2.66	2.64	2.32	1.59	2.37
Return on Equity (ROE)	4.99%	2.64%	2.11%	3.24%	3.78%	10.45%
Return on Assets (ROA)	4.43%	3.89%	2.84%	2.07%	2.04%	3.96%
Return on Capital (ROIC)	5.12%	4.43%	4.53%	3.30%	2.26%	4.42%
Return on Capital Employed (ROCE)	8.40%	6.90%	5.10%	3.50%	3.60%	7.00%
Earnings Yield	3.75%	2.76%	0.46%	2.82%	1.93%	4.37%
FCF Yield	10.48%	11.79%	-0.06%	-4.35%	3.57%	5.86%
Dividend Yield	-	-	-	-	-	1.53%
Payout Ratio	-	0.61%	-	0.32%	133.76%	18.31%
Buyback Yield / Dilution	9.25%	-0.02%	0.01%	0.26%	0.58%	-0.06%
Total Shareholder Return	-	-0.02%	0.01%	0.26%	0.58%	1.47%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.